Adjuvant Global Health Technology Fund De, L.p. - Net Worth and Insider Trading

Adjuvant Global Health Technology Fund De, L.p. Net Worth

The estimated net worth of Adjuvant Global Health Technology Fund De, L.p. is at least $46 Million dollars as of 2024-06-21. Adjuvant Global Health Technology Fund De, L.p. is the 10% Owner of Elevance Health Inc and owns about 2,597,380 shares of Elevance Health Inc (ANTX) stock worth over $41 Million. Adjuvant Global Health Technology Fund De, L.p. is also the 10% Owner of AN2 Therapeutics Inc and owns about 2,373,500 shares of AN2 Therapeutics Inc (ANTX) stock worth over $5 Million. Details can be seen in Adjuvant Global Health Technology Fund De, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Adjuvant Global Health Technology Fund De, L.p. has not made any transactions after 2024-01-16 and currently still holds the listed stock(s).

Transaction Summary of Adjuvant Global Health Technology Fund De, L.p.

To

Adjuvant Global Health Technology Fund De, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Adjuvant Global Health Technology Fund De, L.p. owns 1 companies in total, including AN2 Therapeutics Inc (ANTX) .

Click here to see the complete history of Adjuvant Global Health Technology Fund De, L.p.’s form 4 insider trades.

Insider Ownership Summary of Adjuvant Global Health Technology Fund De, L.p.

Ticker Comapny Transaction Date Type of Owner
ANTX AN2 Therapeutics Inc 2024-01-16 10 percent owner

Adjuvant Global Health Technology Fund De, L.p. Latest Holdings Summary

Adjuvant Global Health Technology Fund De, L.p. currently owns a total of 2 stocks. Among these stocks, Adjuvant Global Health Technology Fund De, L.p. owns 2,597,380 shares of Elevance Health Inc (ANTX) as of March 29, 2022, with a value of $41 Million and a weighting of 89.42%. Adjuvant Global Health Technology Fund De, L.p. also owns 2,373,500 shares of AN2 Therapeutics Inc (ANTX) as of January 16, 2024, with a value of $5 Million and a weighting of 10.58%.

Latest Holdings of Adjuvant Global Health Technology Fund De, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ANTX Elevance Health Inc 2022-03-29 2,597,380 15.84 41,142,499
ANTX AN2 Therapeutics Inc 2024-01-16 2,373,500 2.05 4,865,675

Holding Weightings of Adjuvant Global Health Technology Fund De, L.p.


Adjuvant Global Health Technology Fund De, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Adjuvant Global Health Technology Fund De, L.p. has made a total of 1 transactions in Elevance Health Inc (ANTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Elevance Health Inc is the acquisition of 166,666 shares on March 29, 2022, which cost Adjuvant Global Health Technology Fund De, L.p. around $2 Million.

According to the SEC Form 4 filings, Adjuvant Global Health Technology Fund De, L.p. has made a total of 8 transactions in AN2 Therapeutics Inc (ANTX) over the past 5 years, including 1 buys and 7 sells. The most-recent trade in AN2 Therapeutics Inc is the sale of 100,000 shares on January 16, 2024, which brought Adjuvant Global Health Technology Fund De, L.p. around $2 Million.

Insider Trading History of Adjuvant Global Health Technology Fund De, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Adjuvant Global Health Technology Fund De, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Adjuvant Global Health Technology Fund De, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Adjuvant Global Health Technology Fund De, L.p. is -47.3%. GuruFocus also compares Adjuvant Global Health Technology Fund De, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Adjuvant Global Health Technology Fund De, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Adjuvant Global Health Technology Fund De, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Adjuvant Global Health Technology Fund De, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 4.13 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 14.92 LIMIT LIMIT LIMIT LIMIT LIMIT

Adjuvant Global Health Technology Fund De, L.p. Ownership Network

Ownership Network List of Adjuvant Global Health Technology Fund De, L.p.

No Data

Ownership Network Relation of Adjuvant Global Health Technology Fund De, L.p.

Insider Network Chart

Adjuvant Global Health Technology Fund De, L.p. Owned Company Details

What does AN2 Therapeutics Inc do?

Who are the key executives at AN2 Therapeutics Inc?

Adjuvant Global Health Technology Fund De, L.p. is the 10 percent owner of AN2 Therapeutics Inc. Other key executives at AN2 Therapeutics Inc include Chief Strategy Officer Kevin Michael Krause , director & Chief Executive Officer Eric Easom , and 10 percent owner Ra Capital Healthcare Fund Lp .

AN2 Therapeutics Inc (ANTX) Insider Trades Summary

Over the past 18 months, Adjuvant Global Health Technology Fund De, L.p. made 7 insider transaction in AN2 Therapeutics Inc (ANTX) with a net sale of 223,880. Other recent insider transactions involving AN2 Therapeutics Inc (ANTX) include a net sale of 223,880 shares made by Kabeer Aziz , a net sale of 10,000 shares made by Kevin Michael Krause , and a net purchase of 7,223 shares made by Eric Easom .

In summary, during the past 3 months, insiders sold 0 shares of AN2 Therapeutics Inc (ANTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 565,631 shares of AN2 Therapeutics Inc (ANTX) were sold and 1,787,778 shares were bought by its insiders, resulting in a net purchase of 1,222,147 shares.

AN2 Therapeutics Inc (ANTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

AN2 Therapeutics Inc Insider Transactions

No Available Data

Adjuvant Global Health Technology Fund De, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Adjuvant Global Health Technology Fund De, L.p.. You might contact Adjuvant Global Health Technology Fund De, L.p. via mailing address: C/o Adjuvant Capital, L.p., 501 Fifth Avenue, Suite 1404, New York Ny 10017.

Discussions on Adjuvant Global Health Technology Fund De, L.p.

No discussions yet.